Isosorbide
JFDA label: ISOCARD 10mg TAB.
Mechanism of Action
— Osmotic agent
Indications
Approved
- Angina pectoris, prevention
Off-label
- Esophageal spastic disorders
- Heart failure with reduced ejection fraction (intolerance to an ACE inhibitor or an angiotensin receptor blocker)
- Heart failure with reduced ejection fraction, NYHA Class III-IV (African-American [self-identified] patients)
Contraindications
Source: Lexicomp
- Additional contraindications (not in US labeling): Cardiogenic shock or risk of cardiogenic shock developing Absolute
- Hypersensitivity to isosorbide dinitrate or any component of the formulation Absolute
- concurrent use with phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil, or avanafil) Absolute
- concurrent use with riociguat Absolute
Adverse Reactions
Cardiac disorders (5)
Not Known Hypotension · orthostatic hypotension · rebound hypertension (uncommon) · syncope (uncommon) · unstable angina pectoris (uncommon)
Nervous system disorders (2)
Not Known Dizziness (related to blood pressure changes) · headache (most common)
Blood and lymphatic system disorders (1)
Not Known Methemoglobinemia (rare; overdose)
Dosing
Source: Lexicomp
Warnings & Precautions
Source: Lexicomp
Hypotension/bradycardia
Severe hypotension can occur; paradoxical bradycardia and increased angina pectoris can accompany hypotension. Orthostatic hypotension can also occur; ethanol can accentuate this. Use with caution in volume depletion and hypotension, and use with extreme caution with inferior wall MI and suspected right ventricular infarctions. Severe hypotension, particularly with upright posture, may occur with even small doses.
Intracranial pressure increased
Nitrates may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (Rangel-Castilla 2008). Disease-related concerns:
Cardiovascular disease
Not recommended in patients with acute MI or HF (cannot easily reverse effects if adverse events develop).
Hypertrophic cardiomyopathy (HCM)
Avoid use in patients with HCM with outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (ACCF/AHA [Gersh 2011]). Concurrent drug therapy issues:
Drug-drug interactions
Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Other warnings/precautions:
Tolerance
Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect. When used for HF in combination with hydralazine, tolerance is less of a concern (Gogia 1995).
Pregnancy & Lactation
Pregnancy
Adverse events have been observed in some animal reproduction studies. Nitric oxide donors, such as isosorbide, have been evaluated for pre-eclampsia and cervical ripening; isosorbide dinitrate use in these conditions is not currently recommended (Kalidindi 2012; Ramirez 2011).
Lactation
It is not known if isosorbide dinitrate is excreted in breast milk. The manufacturer recommends that caution be exercised when administering isosorbide dinitrate to nursing women.
Monitoring
| Clinical pearl | Blood pressure, heart rate |
|---|
Chemistry & Properties
| Formula | C6H10O4 |
|---|---|
| Molecular weight | 146.14 g/mol |
| IUPAC name | (3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol |
| CAS | 652-67-5 |
| PubChem CID | 12597 |
| InChIKey | KLDXJTOLSGUMSJ-JGWLITMVSA-N |
| logP | -1.49 (XLogP -1.4) |
| Polar surface area | 58.92 Ų |
| H-bond acceptors / donors | 4 / 2 |
| Drug-likeness (QED) | 0.44 |
| Lipinski violations | 0 |
SMILES
O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OBiology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|---|
| Half-life | 2.732 h |
| Volume of distribution | 0.594 L/kg |
| Protein binding | 6.8% |
| BBB penetrant | No |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Drug–drug interactions (30, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Nitrous acid | major | |
| Alimemazine | moderate | |
| Amifostine | moderate | |
| Benzocaine (topical) | moderate | |
| Brimonidine (ophthalmic) | moderate | |
| Brimonidine (topical) | moderate | |
| Cinchocaine (topical) | moderate | |
| Cocaine (nasal) | moderate | |
| Cocaine (topical) | moderate | |
| Epoprostenol | moderate | |
| Iloprost | moderate | |
| Irinotecan | moderate | |
| Irinotecan (liposomal) | moderate | |
| Lidocaine (ophthalmic) | moderate | |
| Lidocaine (topical) | moderate | |
| Methdilazine | moderate | |
| Minoxidil (topical) | moderate | |
| Oxybuprocaine (ophthalmic) | moderate | |
| Ozanimod | moderate | |
| Pentoxifylline | moderate | |
| Procarbazine | moderate | |
| Promethazine | moderate | |
| Rosiglitazone | moderate | |
| Selexipag | moderate | |
| Tetracaine (ophthalmic) | moderate | |
| Tetracaine (topical) | moderate | |
| Thiethylperazine | moderate | |
| Treprostinil | moderate | |
| Demeclocycline | minor | |
| Doxycycline | minor |
Registered Products (16)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Isoket Tablet | Tablet 5 mg | 50 tab pack varies | Suleiman Tannous & Sons Co. Ltd | 1.890 |
| ISOCARD 10mg TAB. | Tablet 10 mg | 100 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 2.300 |
| Cardipine 5 Sublingual Tablets | Tablet 5 mg | 100 tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.400 |
| Isoket Retard Tablet | Tablet 20 mg | 50 tab | Suleiman Tannous & Sons Co. Ltd | 2.790 |
| ISORDIL SUBLINGUAL tabs | Tablet 5 mg | 100 tab | Arab Company for Medical & Agricultural Products | 2.870 |
| ISORDIL TAB. | Tablet 10 mg | 100 tab | Arab Company for Medical & Agricultural Products | 2.870 |
| Isobide | Capsule 40 mg | 20 cap | Khoury Drug Store | 3.000 |
| Isobide | Capsule 20 mg | 20 cap | Khoury Drug Store | 3.000 |
| Isoket Tablet | Tablet 10 mg | 100 tab | Suleiman Tannous & Sons Co. Ltd | 3.640 |
| Isoket Tablet | Tablet 5 mg | 100 tab pack varies | Suleiman Tannous & Sons Co. Ltd | 3.640 |
| Isosorbide Dinitrate | Tablet 20 mg | 100 tab | Ù Ø³ØªÙØ¯Ø¹ أدÙÙØ© اÙÙÙÙÙÙÙ | 3.710 |
| Isoket Retard Tablet | Tablet 40 mg | 50 tab | Suleiman Tannous & Sons Co. Ltd | 4.780 |
| ISORDIL TAB | Tablet 30 mg | 100 tab | Arab Company for Medical & Agricultural Products | 5.580 |
| Isosorbide Dinitrate | Tablet 40 mg | 100 tab | Ù Ø³ØªÙØ¯Ø¹ أدÙÙØ© اÙÙÙÙÙÙÙ | 6.080 |
| ISOCARD 10 mg TABS. | Tablet 10 mg | 500 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 10.580 |
| Isoket Ampules I.V. | Ampoule 0.1 %[1 mg/ml] | 10 amp | Suleiman Tannous & Sons Co. Ltd | — |